[Polychemotherapy of inoperable bronchogenic carcinoma: preliminary results (author's transl)].
Preliminary results indicate that BACO and SAKK are capable of inducing remission in 80-90% of cases of small-cell bronchogenic carcinoma; these remissions last for about 6 months and not only prolong, but improve the quality of, life. In view of the small number of cases so far observed no assessment can as yet be made of the superiority of one or the other method concerning the incidence and duration of remissions and survival time. In cases of squamous cell cancer the two therapeutic methods succeeded in only 30-40% of the patients in inducing partical remissions and they did not appear to improve the quality of life. The question whether the treatment actually prolongs life as compared with the natural course of the disease remains open.
D000970:Antineoplastic Agents / Q000627:therapeutic use; D001761:Bleomycin / Q000627:therapeutic use; D002283:Carcinoma, Bronchogenic / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D004317:Doxorubicin / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011788:Quality of Life; D014750:Vincristine / Q000627:therapeutic use
D000970:Antineoplastic Agents; D001761:Bleomycin; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D006918:Hydroxyurea; D008727:Methotrexate
Polychemotherapie des inoperablen Bronchialkarzinoms--Ergebnisse einer randomisierten und kontrollierten Studie.